EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Comparisons

What should the board approve—and what should remain conditional?

Dose Diligence research deskSection 03 · Page 11 of 12Last updated 17 Nov 2026

Approve a documented operating model and a bounded rollout, not merely a supplier name.

A decision pack should contain:

  • A route diagram showing the product, prescription, payment, ownership and data flows.
  • Product-specific eligibility and quality sign-offs, with unresolved issues visible.
  • A facility-by-state launch matrix.
  • Separate clinic-cost and patient-affordability models.
  • Introductory, continuing, offer-loss and interruption scenarios.
  • Pilot evidence with agreed metric definitions.
  • A tested fallback and named escalation owners.
  • Contracted transition rights and quantified minimum-commitment exposure.
  • A monitoring calendar for prices, licences, safety communications and regulatory changes.

Suggested rollout: complete documentary gates first; then run a controlled pilot across representative cohorts; expand only after observing the relevant refill and exception workflows. The appropriate duration depends on the prescribed supply cycles and launch risks—not an arbitrary promise to complete everything in 30 days.

The core procurement discipline is straightforward: compare the same operating problem, keep patient expenditure separate from clinic economics, and require evidence for the exact route being approved. A low headline price, a familiar platform name or a registration record cannot substitute for that work.

Sources cited on this page

    See the section’s source register for the research context.

    Section sources →